SARS-CoV-2 infection induces the production of aberrant type I IFN in cultured cells and COVID-19 patients.28 This phenomenon is at least partly due to the various viral mechanisms for evasion and suppression of IFN activation.29,30 Several SARS-CoV-2 proteins, including nsp1, nsp3, nsp6, nsp8, nsp12, nsp13, nsp14, nsp15, ORF3, ORF6, ORF8, ORF9b, M, and N, have been reported to inhibit type I IFN activation and the corresponding response.14,31–39 Here, we report that nsp12 of SARS-CoV-2 attenuates type I IFN induction by inhibiting IRF3 nuclear translocation. The gene discussed is IRF3; the disease is COVID-19.